INAB IN8BIO INC

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the:

H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Date/Time Tuesday, February 25, 2025, at 11:00 a.m. ET.

Webcast Link

A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at .

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit .

Investor & Corporate Contact

Glenn Schulman, PharmD, MPH

IN8bio, Inc.

203.494.7411

Media Contact

Kimberly Ha

KKH Advisors

917.291.5744



EN
24/02/2025

Underlying

INABIN8BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conferen...

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025 NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA. William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcom...

March 18, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and...

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-freeExpanded pipeline with INB-600 platform, featuring novel gamma-delta T Cell engager (TCE) targeting CD19 for potential use in oncology and autoimmune diseasesContinued operational execution with strengthened strategic focus on aligning resources in an effort to drive ...

March 13, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platfo...

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potencyINB-619, a next generation γδ TCE targeting CD19, eradicates B cells in preclinical models, maintaining depletion over time as γδ T cells expand in response to TCE stimulation γδ TCE targets and expands both Vδ1+ and Vδ2+ T cells, potentially leading to longer lasting immune responses and deeper B cell depletionUnlike traditional TCEs and CAR...

March 3, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 45th  Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at . About IN8bio IN8bio is a clinical-stage biopharmac...

February 26, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtu...

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the: H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceDate/Time Tuesday, February 25, 2025, at 11:00 a.m. ET. Webcast Link A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website a...

February 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch